Zura Bio Relocates Principal Executive Offices to Henderson, NV

TL;DR

**Zura Bio just changed its corporate address and phone number, nothing major for traders.**

AI Summary

Zura Bio Ltd. filed an 8-K on January 11, 2024, to update its principal executive offices from La Jolla, CA to 1489 W. Warm Springs Rd. #110, Henderson, Nevada 89014. This change in address, along with an updated phone number to (702) 757-6133, is a routine administrative update and does not signal any immediate operational or financial shifts. For investors, this filing primarily indicates a logistical change rather than a strategic one, so it's unlikely to directly impact the stock's value unless it's part of a larger, unannounced corporate restructuring.

Why It Matters

This filing is an administrative update regarding Zura Bio's new principal executive office address and phone number. It's important for investors to have accurate contact information for the company, but this specific change doesn't indicate a shift in business operations or financial health.

Risk Assessment

Risk Level: low — This filing is purely administrative, reporting a change of address and phone number, which carries minimal risk to investors.

Analyst Insight

A smart investor would note this administrative change but understand it has no immediate impact on Zura Bio's operational or financial performance. No specific action is warranted based solely on this filing.

Key Numbers

• $0.0001 — par value per share (par value of Zura Bio's Class A Ordinary Shares)

Key Players & Entities

• Zura Bio Ltd. (company) — the registrant filing the 8-K
• 1489 W. Warm Springs Rd. #110, Henderson, Nevada 89014 (location) — new principal executive offices
• (702) 757-6133 (phone_number) — new registrant's telephone number
• La Jolla, CA (location) — former business address
• $0.0001 (dollar_amount) — par value per share of Class A Ordinary Shares

FAQ

Key Financial Figures

• $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar
• $11.50 — Ordinary Share at an exercise price of $11.50 per share ZURAW The Nasdaq Stock Ma

Filing Documents

• tm243224d1_8k.htm (8-K) — 33KB
• tm243224d1_ex99-1.htm (EX-99.1) — 36KB
• tm243224d1_ex99-1img001.jpg (GRAPHIC) — 91KB
• tm243224d1_ex99-1img002.jpg (GRAPHIC) — 342KB
• tm243224d1_ex99-1img003.jpg (GRAPHIC) — 191KB
• tm243224d1_ex99-1img004.jpg (GRAPHIC) — 227KB
• tm243224d1_ex99-1img005.jpg (GRAPHIC) — 169KB
• tm243224d1_ex99-1img006.jpg (GRAPHIC) — 185KB
• tm243224d1_ex99-1img007.jpg (GRAPHIC) — 174KB
• tm243224d1_ex99-1img008.jpg (GRAPHIC) — 226KB
• tm243224d1_ex99-1img009.jpg (GRAPHIC) — 159KB
• tm243224d1_ex99-1img010.jpg (GRAPHIC) — 177KB
• tm243224d1_ex99-1img011.jpg (GRAPHIC) — 74KB
• tm243224d1_ex99-1img012.jpg (GRAPHIC) — 211KB
• tm243224d1_ex99-1img013.jpg (GRAPHIC) — 182KB
• tm243224d1_ex99-1img014.jpg (GRAPHIC) — 184KB
• tm243224d1_ex99-1img015.jpg (GRAPHIC) — 176KB
• tm243224d1_ex99-1img016.jpg (GRAPHIC) — 142KB
• tm243224d1_ex99-1img017.jpg (GRAPHIC) — 152KB
• tm243224d1_ex99-1img018.jpg (GRAPHIC) — 154KB
• tm243224d1_ex99-1img019.jpg (GRAPHIC) — 117KB
• 0001104659-24-003374.txt ( ) — 4889KB
• zura-20240111.xsd (EX-101.SCH) — 3KB
• zura-20240111_def.xml (EX-101.DEF) — 26KB
• zura-20240111_lab.xml (EX-101.LAB) — 36KB
• zura-20240111_pre.xml (EX-101.PRE) — 25KB
• tm243224d1_8k_htm.xml (XML) — 5KB

01

Item 7.01 Regulation FD Disclosure. On January 11, 2024, representatives of Zura Bio Limited, a Cayman Islands exempted company (the "Company"), began making presentations to banks and analysts using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1 (the "Investor Presentation"), which is incorporated herein by reference. The Company has filed the Investor Presentation on its website and expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ending December 31, 2024. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a fili

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Number Description 99.1 Investor Presentation dated January 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 11, 2024 ZURA BIO LIMITED By: /s/ Kim Davis Kim Davis Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR